The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Allogeneic Hematopoietic Stem Cell Transplantation

Sex: All

Ages: 18 Years – 65 Years

Enrollment: 60

Sponsor: Nanfang Hospital of Southern Medical University

Summary

This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD AML patients after allo-HSCT in terms of gut microbiome.

Eligibility Criteria

Inclusion Criteria:FLT3-ITD Positive AMLAllo-HSCT RecipientsExclusion Criteria:Intolerance to sorafenib pre-transplantationCardiac dysfunction (particularly congestive heart failure)Hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase> 2 times the upper limit of normal)Renal dysfunction (creatinine clearance rate < 30 mL/min)Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)Patients with any conditions not suitable for the trial (according to the investigators' decision)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05596981). StuddyBuddy aggregates publicly available trial information.